<DOC>
	<DOCNO>NCT02903836</DOCNO>
	<brief_summary>Study Determine Safety , Tolerability , Pharmacokinetics Efficacy Oral Nafithromycin Versus Oral Moxifloxacin Treatment Community-Acquired Bacterial Pneumonia ( CABP ) Adults</brief_summary>
	<brief_title>Phase II Study Oral Nafithromycin CABP</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Meet clinical criterion CABP base following : 1 . Clinical symptom ( new worsen ) 2 . Vital sign abnormality 3 . Laboratory abnormalities 4 . Radiographic evidence CABP 5 . PORT score 1 . Subjects follow confirm suspected type pneumonia : 1 . Aspiration pneumonia 2 . Hospitalacquired bacterial pneumonia ( HABP ) 3 . Healthcareassociated bacterial pneumonia ( HCAP ) 4 . Ventilatorassociated bacterial pneumonia ( VABP ) 5 . Pneumonia may cause pathogen ( ) resistant either study drug 2 . Receipt 1 dose ( ) potentially effective systemic antibacterial treatment treatment current CABP 3 . Suspected confirm noninfectious cause pulmonary infiltrates 4 . Subjects require concomitant adjunctive additional potentiallyeffective systemic antibacterial treatment management CABP</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>